Pacific Biosciences of California PACB Deferred Revenue Timing Percentage

Deferred Revenue Timing Percentage at other companies

IlluminaILMN

——

DanaherDHR

——

Charles River LaboratoriesCRL

——

Other financials

Income statement

See full

Revenue$37.2M+0.1%

Gross profit$12.8M+1,037%

Operating income-$8.4M+98.1%

Net income-$8.3M+98.1%

EPS (diluted)-$0.03+97.9%

Balance sheet

See full

Cash & equivalents$57.9M-4.7%

Total debt$59.3M+12.1%

Total equity$2.4M-97.4%

Total assets$782.4M-9.1%

Cash flow

See full

Operating cash flow-$44.7M-1.4%

CapEx$3.0M+119%

Free cash flow-$47.7M-5.0%

Valuation

See full

Market cap$496.96M+30.4%

Enterprise value$498.38M+33.5%

P/S3.1×+0.6×

Profitability

See full

Gross margin37.5%+21.3pp

Operating margin-83.3%-38.2pp

Net margin-80.3%-36.1pp

FCF margin-72.6%-20.0pp

Returns & leverage

See full

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligationPercentage.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's deferred revenue timing percentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacific Biosciences of California's deferred revenue timing percentage?: Pacific Biosciences of California (PACB) reported deferred revenue timing percentage of 78% in Q1 2026.